Cellular CD4 T cell responses to the diphtheria-derived carrier protein of conjugated pneumococcal vaccine and antibody response to pneumococcal vaccination in HIV-infected adults

Clinical Infectious Diseases

Volumn 50, Issue 8, 2010, Pages 1174-1183

  Rabian, Claire ^a,e   Tschöpe, Inga ^f   Lesprit, Philippe ^g   Katlama, Christine ^c   Molina, Jean Michel ^b   Meynard, Jean Luc ^d   Delfraissy, Jean François ⁱ   Chêne, Geneviève ^f   Levy, Yves ^g,h  

^a Laboratoire d'Immunologie et d'HIstocompatiblllté   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d St Antolne Hospital   (France)

^e French National Agency for Research on AIDS and Viral Hepatitis   (France)

^f INSERM   (France)

^g HENRI MONDOR HOSPITAL   (France)

^h INSERM U955   (France)

ⁱ ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; CD4 ANTIGEN; CHEMOKINE RECEPTOR CXCR5; DIPHTHERIA TOXOID CRM197; GAMMA INTERFERON; IMMUNOGLOBULIN G; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; PNEUMOCOCCUS VACCINE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTIBODY RESPONSE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIPHTHERIA; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; MEMORY CELL; MEMORY T LYMPHOCYTE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STREPTOCOCCUS PNEUMONIAE; TH1 CELL; VACCINATION;

ADULT; ANTIBODIES, BACTERIAL; BACTERIAL PROTEINS; CARRIER PROTEINS; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; FEMALE; HIV INFECTIONS; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC MEMORY; MALE; MIDDLE AGED; PNEUMOCOCCAL VACCINES; TH1 CELLS; VACCINATION;

EID: 77950255821     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/651418     Document Type: Article

References (40)

1. Frankel RE, Virata M, Hardalo C, Altice FL, Friedland G. Invasive pneumococcal disease: clinical features, serotypes, and antimicrobial resistance patterns in cases involving patients with and without human immunodeficiency virus infection. Clin Infect Dis 1996; 23: 577-584.
2. Nuorti JP, Butler JC, Gelling L, Kool JL, Reingold AL, Vugia DJ. Epidemiologic relation between HIV and invasive pneumococcal disease in San Francisco Country, California. Ann Intern Med 2000; 132: 182-190.
3. Jones N, Huebner R, Khoosal M, Crewe-Brown H, Klugman K. The impact of HIV on Streptococcus pneumoniae bacteraemia in a South African population. AIDS 1998; 12: 2177-2184.
4. Kovacs JA, Masur H. Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection. N Engl J Med 2000; 342: 1416-1429.
5. French N, Nakiyingi J, Carpenter LM, et al. 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet 2000; 355: 2106-2111.
6. Dworkin MS, Ward JW, Hanson DL, Jones JL, Kaplan JE. Pneumococcal disease among human immunodeficiency virus-infected persons: incidence, risk factors, and impact of vaccination. Clin Infect Dis 2001; 32: 794-800.
7. Breiman RF, Keller DW, Phelan MA, et al. Evaluation of effectiveness of the 23-valent pneumococcal capsular polysaccharide vaccine for HIV-infected patients. Arch Intern Med 2000; 160: 2633-2638.
8. Hung CC, Chen MY, Hsieh SM, Hsiao CF, Sheng WH, Chang SC. Clinical experience of the 23-valent capsular polysaccharide pneumococcal vaccination in HIV-1-infected patients receiving highly active antiretroviral therapy: a prospective observational study. Vaccine 2004; 22: 2006-2012.
9. Rodriguez-Barradas MC, Musher DM, Lahart C, et al. Antibody to capsular polysaccharides of Streptococcus pneumoniae after vaccination of human immunodeficiency virus-infected subjects with 23-valent pneumococcal vaccine. J Infect Dis 1992; 165: 553-556.
10. Rodriguez-Barradas MC, Alexandraki I, Nazir T, et al. Response of human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy to vaccination with 23-valent pneumococcal polysaccharide vaccine. Clin Infect Dis 2003; 37: 438-447.
11. Ahmed F, Steinhoff MC, Rodriguez-Barradas MC, Hamilton RG, Musher DM, Nelson KE. Effects of human immunodeficiency virus type 1 infection on the antibody response to a glycoprotein conjugate pneumococcal vaccine: results from a randomized trial. J Infect Dis 1996; 173: 83-90.
12. Renneis MB, Edwards KM, Keyserling HL, et al. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants. Pediatrics 1998; 101: 604-611.
13. Dagan R, Mclamcd R, Zamir O, Leroy O. Safety and immunogenicity of tetravalent pneumococcal vaccines containing 6B, 14, 19F and 23F polysaccharides conjugated to either tetanus toxoid or diphtheria toxoid in young infants and their boosterability by native polysaccharide antigens. Pediatr Infect Dis J 1997; 16: 1053-1059.
14. Ahman H, Käyhty H, Lehtonen H, Leroy O, Froeschle J, Eskola J. Streptococcus pneumoniae capsular polysaccharide-diphtheria toxoid conjugate vaccine is immunogenic in early infancy and able to induce immunologic memory. Pediatr Infect Dis J 1998; 17: 211-216.
15. Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein polysaccharide conjugate vaccine. N Engl J Med 2003; 348: 1737-1746.
16. Madhi SA, Adrian P, Kuwanda L, et al. Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in immunodeficient virus infected and non-infected children in the absence of a booster dose of vaccine. Vaccine 2007; 25: 2451-2457.
17. Bliss SJ, O'Brien KL, Janoff EN, et al. The evidence for using conjugate vaccines to protect HIV-infected children against pneumococcal disease. Lancet Infect Dis 2008; 8: 67-80.
18. Lesprit P, Pédrono G, Molina JM, et al. Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults. AIDS 2007; 21: 2425-2434.
19. Wernette CM, Frasch CE, Madore D, et al. Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides. Clin Diagn Lab Immunol 2003; 10: 514-519.
20. Pédrono G, Thiébaut R, Ahmadou A, et al. A new endpoint definition improved clinical relevance and statistical power in a vaccine trial. J Clin Epidemiol 2009; 62: 1054-1061.
21. Fournier S, Rabian C, Alberti C, et al. Immune recovery under highly active antiretroviral therapy is associated with restoration of lymphocyte proliferation and interferon-gamma production in the presence of Toxoplasma gondii antigens. J Infect Dis 2001; 183: 1586-1591.
22. Alfonzo M, Blanc D, Troadec C, Eliaszewicz M, Gonzalez G, ScottAlgara D. Partial restoration of cytokine profile despite reconstitution of cytomegalovirus-specifk cell-mediated immunity in human immunodeficiency vims-infected patients during highly active antiretroviral treatment. Scand J Immunol 2003; 57: 375-383.
23. Schaerli P, Willimann K, Lang AB, Lipp M, Loetscher P, Moser B. CXC chemokine receptor 5 expression defines follicular homing T cells with B cell helper function. J Exp Med 2000; 192: 1553-1562.
24. Schaerli P, Loetscher P, Moser B. Cutting edge: induction of follicular homing precedes effector Th cell development. J Immunol 2001; 167: 6082-6086.
25. Kim CH, Rott LS, Clark-Lewis I, Campbell DJ, Wu L, Butcher EC. Subspecialization of CXCR5+ T cells: B helper activity is focused in a germinal center-localized subset of CXCR5+ T cells. J Exp Med 2001; 193: 1373-1381.
26. Legier DF, Loetscher M, Roos RS, Lewis-Clark I, Baggiolini M, Moser B. B cell-attracting chemokine 1, a human CXC chemokine expressed in lymphoid tissues, selectively attracts B lymphocytes via BLR1/CXCR5. J Exp Med 1998; 187: 655-660.
27. Warnatz K. Dissecting CXCR5+ T cell populations: on the quest for a better understanding of B cell help during T dependent antibody responses. Eur J Immunol 2006; 36: 1662-1664.
28. Mond JJ, Lees A, Snapper CM. T cell-independent antigens type 2. Annu Rev Immunol 1995; 13: 655-692.
29. Kamboj KK, King CL, Greenspan NS, Kirchner HL, Schreiber JR. Immunization with Haemophilus influenzae type b-CRM(197) conjugate vaccine elicits a mixed ThI and Th2 CD4+ T cell cytokine response that correlates with the isotype of antipolysaccharide antibody. J Infect Dis 2001; 184: 931-935.
30. Kamboj KK, Kirchner HL, Kimmel R, Greenspan NS, Schreiber JR. Significant variation in serotype-specific immunogenicity of seven-valent streptococcus pneumoniae capsular polysaccharide-CRM-197 conjugate vaccine occurs despite vigorous T cell help induced by carrier protein. J Infect Dis 2003; 187: 1629-1638.
31. McCool T, Harding CV, Greenspan NS, Schreiber JR. B- and T-cell immune responses to pneumococcal conjugate vaccines: divergence between carrier- and polysaccharide-specific immunogenicity. Infect Immun 1999; 67: 4862-4869.
32. Lange CG, Lederman MM, Medvik K, et al. Nadir CD4+ T-cell count and numbers of CD28+ CD4+ T-cells predict functional responses to immunizations in chronic HIV-I infection. AIDS 2003; 17: 2015-2023.
33. Kroon FP, van Dissel JT, Labadie J, van Loon AM, van Fürth R. Antibody response to diphtheria, tetanus, and poliomyelitis vaccines in relation to the number of CD4+ T lymphocytes in adults infected with human immunodeficiency virus. Clin Infect Dis 1995; 21: 1197-1203.
34. Chang Q, Abadi J, Alpert P, Pirofski L. A pneumococcal capsular polysaccharide vaccine induces a repertoire shift with increased VH3 expression in peripheral B cells from human immunodeficiency virus (HIV)-uninfected but not HIV-infected persons. J Infect Dis 2000; 181: 1313-1321.
35. Abadi J, Friedman J, Mageed RA, Jefferis R, Rodriguez-Barradas MC, Pirofski L. Human antibodies elicited by a pneumococcal vaccine express idiotypic determinants indicative of V(H)3 gene segment usage. J Infect Dis 1998; 178: 707-716.
36. Subramaniam KS, Segal R, Lyles RH, Rodriguez-Barradas MC, Pirofski LA. Qualitative change in antibody responses of human immunodeficiency virus-infected individuals to pneumococcal capsular polysaccharide vaccination associated with highly active antiretroviral therapy. J Infect Dis 2003; 187: 758-768.
37. Anttila M, Eskola J, Ahman H, Käyhty H. Avidity of IgG for Streptococcus pneumoniae type 6B and 23F polysaccharides in infants primed with pneumococcal conjugates and boosted with polysaccharide or conjugate vaccines. J Infect Dis 1998; 177: 1614-1621.
38. French N, Moore M, Haikala R, Käyhty H, Gilks CF. A case control study to investigate serological correlates of clinical failure of 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults. J Infect Dis 2004; 190: 707-712.
39. Lewden C, Chêne G, Morlat P, et al. HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J Acquir Immune Defic Syndr 2007; 46: 72-77.
40. Le Moing V, Rabaud C, Journot V, et al. Incidence and risk factors of bacterial pneumonia requiring hospitalization in HIV-infected patients started on a protease inhibitor-containing regimen. HIV Med 2006; 7: 261-267.